Interventions for idiopathic steroid-resistant nephrotic syndrome in children.

Elisabeth M. Hodson, Narelle S. Willis, Jonathan C. Craig

Research output: Contribution to journalReview articlepeer-review

51 Citations (Scopus)
14 Downloads (Pure)

Abstract

Background

The majority of children who present with their first episode of nephrotic syndrome achieve remission with corticosteroid therapy. Children who fail to respond may be treated with immunosuppressive agents including calcineurin inhibitors (cyclosporin or tacrolimus) and with non‐immunosuppressive agents such as angiotensin‐converting enzyme inhibitors (ACEi). Optimal combinations of these agents with the least toxicity remain to be determined.

Objectives

To evaluate the benefits and harms of interventions used to treat idiopathic steroid‐resistant nephrotic syndrome (SRNS) in children.

Search methods

Randomised controlled trials (RCTs) were identified from the Cochrane Renal Group's specialised register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and reference lists of articles.

Selection criteria

RCTs and quasi‐RCTs were included if they compared different immunosuppressive agents or non‐immunosuppressive agents with placebo, prednisone or other agent given orally or parenterally in children aged three months to 18 years with SRNS.

Data collection and analysis

Two authors independently searched the literature, determined study eligibility, assessed quality and extracted data. For dichotomous outcomes, results were expressed as risk ratios (RR) and 95% confidence intervals (CI). Data were pooled using the random effects model.

Main results

Fourteen RCTs (449 children) were included. Cyclosporin when compared with placebo or no treatment significantly increased the number of children who achieved complete remission (three studies, 49 children: RR 7.66, 95% CI 1.06 to 55.34). Cyclosporin significantly increased the number with complete or partial remission compared with IV cyclophosphamide (one study, 32 children: RR 3.40, 95% CI 1.12 to 10.28). There was no significant difference in the number who achieved complete remission between oral cyclophosphamide with prednisone versus prednisone alone (two studies, 91 children: RR 1.06, 95% CI 0.61 to 1.87), IV versus oral cyclophosphamide (one study, 11 children: RR 3.13, 95% CI 0.81 to 12.06), IV cyclophosphamide versus oral cyclophosphamide with IV dexamethasone (one study, 49 children: RR 1.13, 95% CI 0.65 to 1.96), tacrolimus versus cyclosporin (one study, 41 children: RR 0.86, 95% CI 0.44 to 1.66) and azathioprine with prednisone versus prednisone alone (one study, 31 children: RR 0.94, 95% CI 0.15 to 5.84). ACEi significantly reduced proteinuria (two studies, 70 children). No studies were identified comparing high dose steroids and cyclosporin with single agents, placebo or no treatment.

Authors' conclusions

Further adequately powered, well designed RCTs are needed to confirm the efficacy of cyclosporin and to evaluate other regimens for idiopathic SRNS including high dose steroids with cyclosporin.

Original languageEnglish
Article numberCD003594
Number of pages70
JournalCochrane Database of Systematic Reviews
DOIs
Publication statusPublished - 10 Nov 2010
Externally publishedYes

Bibliographical note

Made available in accordance with the publisher's repositories policy

Fingerprint Dive into the research topics of 'Interventions for idiopathic steroid-resistant nephrotic syndrome in children.'. Together they form a unique fingerprint.

Cite this